[1]
V. C. Badalamenti, PharmD, J. W. Buckley, PharmD, and E. T. Smith, PharmD, “Safety of EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release capsules: Review of postmarketing adverse events during the first year”, J of Opioid Management, vol. 8, no. 2, pp. 115–125, Mar. 2012.